Everyone from Jeff Sessions to Roger Goodell has questioned whether or not cannabis has any real medical abilities. An Israeli pharmaceutical company is out to show that it has the ability to cure one major health concern.
Per HERB
CURE Pharmaceutical, a technologically-based drug delivery platform and its partner, Technion-Israel Institute of Technology will be conducting a clinical study to test whether cannabinoid compounds will reduce or eliminate cancerous cells.
Cannabis as a cancer treatment not only for it symptoms but as a possible cure has been hotly debated and researched for some time.
Federally, the government does accept that cancer-related side effects such as decreased appetite, nausea and pain relief can be treated with cannabis, but as for cancer itself, patients and those in the medical field have only been able to anecdotally link cannabis to the destruction of cancerous cells and tumors.
CURE Pharmaceutical is researching this link head on, in its first ever clinical study of this nature. Brian Higuera, the father of a 4-year-old liver cancer patient says there’s a strong possibility after he witnessed the shrinking of his daughter’s liver tumors, along with one that fully disappeared; all after being administered CBD oil.
The tumors are believed to have been removed due to her cannabis use in which [a brand of] CBD (called Real Scientific Hemp Oil) was a major portion of the cannabinoids in her oil along with THC and CBN.
[But] without a study to prove the cannabis oil is what cause the tumors to disappear, many say she is an anecdotal testimony.
CURE’s CEO, Rob Davidson looks to move beyond the anecdotal stage and provide solid proof to back up cases like Sadie’s. His goal is to prove the efficacy of cannabis with hard science behind it.
There is strong anecdotal evidence, but we want to put some science into it. First, we’ll do an in vitro study and see the effects on cancer cells. We can get into human trials pretty quickly in Israel.
Similar studies would be hard to pull off in the U.S. due to federal issues.
